Corvus Pharmaceuticals, Inc.2025财年第三财季实现净利润-10.16百万美元，同比增加74.74%

市场透视11-10

11月10日，Corvus Pharmaceuticals, Inc.（CRVS.US）公布财报，公告显示公司2025财年第三财季净利润为-10.16百万美元，同比增加74.74%；其中营业收入为0.00美元，每股基本收益为-0.12美元。从资产负债表来看，Corvus Pharmaceuticals, Inc.（CRVS.US）总负债8.71百万美元，其中短期债务379000.00美元，资产负债...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2582826302?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-10 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2582826302","market":"us","top_or_hot":-1,"title":"Corvus Pharmaceuticals, Inc.2025财年第三财季实现净利润-10.16百万美元，同比增加74.74%","media":"市场透视","content":"<div>\n<p>11月10日，Corvus Pharmaceuticals, Inc.（CRVS.US）公布财报，公告显示公司2025财年第三财季净利润为-10.16百万美元，同比增加74.74%；其中营业收入为0.00美元，每股基本收益为-0.12美元。从资产负债表来看，Corvus Pharmaceuticals, Inc.（CRVS.US）总负债8.71百万美元，其中短期债务379000.00美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110000223a4950663&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Corvus Pharmaceuticals, Inc.2025财年第三财季实现净利润-10.16百万美元，同比增加74.74%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCorvus Pharmaceuticals, Inc.2025财年第三财季实现净利润-10.16百万美元，同比增加74.74%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-10 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110000223a4950663&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月10日，Corvus Pharmaceuticals, Inc.（CRVS.US）公布财报，公告显示公司2025财年第三财季净利润为-10.16百万美元，同比增加74.74%；其中营业收入为0.00美元，每股基本收益为-0.12美元。从资产负债表来看，Corvus Pharmaceuticals, Inc.（CRVS.US）总负债8.71百万美元，其中短期债务379000.00美元，资产负债...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110000223a4950663&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRVS","symbol_name":"Corvus Pharmaceuticals, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110000223a4950663&s=b","article_id":"2582826302","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110000223a4950663&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2582826302","pubTimestamp":1762704096,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月10日，Corvus Pharmaceuticals, Inc.公布财报，公告显示公司2025财年第三财季净利润为-10.16百万美元，同比增加74.74%；其中营业收入为0.00美元，每股基本收益为-0.12美元。从资产负债表来看，Corvus Pharmaceuticals, Inc.总负债8.71百万美元，其中短期债务379000.00美元，资产负债比为9.24，流动比率为8.30。机构评级：截至2025年11月10日，当前有6家机构对Corvus Pharmaceuticals, Inc.目标价做出预测，其中目标均价为15.33美元，其中最低目标价为11.00美元，最高目标价为24.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"CRVS":"Corvus Pharmaceuticals, Inc."},"translate_title":"Corvus Pharmaceuticals, Inc. achieved net profit of-US $10.16 million in the third fiscal quarter of fiscal year 2025, a year-on-year increase of 74.74%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRVS":1.5},"content_text":"11月10日，Corvus Pharmaceuticals, Inc.（CRVS.US）公布财报，公告显示公司2025财年第三财季净利润为-10.16百万美元，同比增加74.74%；其中营业收入为0.00美元，每股基本收益为-0.12美元。从资产负债表来看，Corvus Pharmaceuticals, Inc.（CRVS.US）总负债8.71百万美元，其中短期债务379000.00美元，资产负债比为9.24，流动比率为8.30。机构评级：截至2025年11月10日，当前有6家机构对Corvus Pharmaceuticals, Inc.目标价做出预测，其中目标均价为15.33美元，其中最低目标价为11.00美元，最高目标价为24.00美元。公司简介：Corvus Pharmaceuticals Inc 是一家处于临床阶段的生物制药公司，致力于开发精准靶向对免疫细胞成熟和功能至关重要的蛋白质的候选产品。其候选产品 soquelitinib 被设计为特异性结合一种参与T细胞激活、T细胞受体信号传导以及T细胞分化和功能的蛋白质——白细胞介素2诱导的T细胞激酶（ITK）。其他产品包括Ciforadenant（CPI-444）和Mupadolimab（CPI-006）。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2582826302","isCrawlerRequest":true}